The announcement was welcome news for those with major depressive disorder, which affects an estimated 8.3% of the adult ...

An emerging treatment for clinical depression has reached an important milestone. This week, the Food and Drug Administration ...

The U.S. Food and Drug Administration expanded approval for Johnson & Johnson's nasal spray, Spravato, to allow it to be used ...

The U.S. Food and Drug Administration approved Johnson & Johnson's ketamine-based nasal spray Spravato to treat adults with ...

Here's what MDs want you to know about Spravato, the latest FDA-approved standalone nasal spray for depression.

"Treatment-resistant depression can be very complicated, especially for patients who do not respond to oral antidepressants ...

Johnson & Johnson (JNJ) stock in focus as FDA expands the label for its depression therapy Spravato (esketamine) allowing its ...

The Food and Drug Administration (FDA) has approved Spravato, a nasal spray developed by Johnson & Johnson, as a standalone ...

The FDA says esketamine, an antidepressant derived from the anesthetic and party drug ketamine, can now be prescribed on its ...

Once seen as an alternative option, the ketamine nasal spray Spravato is now a mainstream prescription for treatment-resistant depression, often recommended in standard guides, he added.

SINGAPORE – Ketamine, the controlled drug best known ... Senior consultant psychiatrist Victor Kwok, who has offered Spravato treatment since Dec 2020, said: “It’s very fast-acting.

A nasal spray therapy for treatment-resistant major depressive disorder (MDD) has now been approved by the Food and Drug Administration (FDA) for use on its own, making it the first-ever approved ...